These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2677 related articles for article (PubMed ID: 20089952)
1. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P; N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952 [TBL] [Abstract][Full Text] [Related]
2. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L; N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L; Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707 [TBL] [Abstract][Full Text] [Related]
4. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. Singer B; Ross AP; Tobias K Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286 [TBL] [Abstract][Full Text] [Related]
5. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L; Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847 [TBL] [Abstract][Full Text] [Related]
6. Fingolimod for relapsing multiple sclerosis: an update. Horga A; Castilló J; Montalban X Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536 [TBL] [Abstract][Full Text] [Related]
7. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L; Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956 [TBL] [Abstract][Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
14. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Yeh EA; Weinstock-Guttman B Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Agashivala N; Kim E Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258 [TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS; N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951 [TBL] [Abstract][Full Text] [Related]
18. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194 [TBL] [Abstract][Full Text] [Related]